Ypsomed grows 20 % in core business and wins record number of customer projects
Simon Michel, CEO and executive member of the Board of Directors of Ypsomed Holding AG
Ypsomed closed the financial year 2025/26 with consolidated revenue of CHF 731.0 million (prior year: CHF 748.9 million).
Ypsomed closed the financial year 2025/26 with consolidated revenue of CHF 731.0 million (prior year: CHF 748.9 million). Delivery Systems, the Company's core business segment, reported revenue of CHF 601.5 million for the period (prior year: CHF 502.3 million), reflecting a year-on-year increase of approximately 20 %. EBIT reached CHF 195.5 million (prior year: CHF 167.0 million), corresponding to an EBIT margin of approximately 33 %. At the Group level, EBIT more than doubled to CHF 246.1 million (prior year: CHF 112.9 million), partly attributable to the book gain following the disposal of the Diabetes Care business. Following the divestiture of the Diabetes Care business, Ypsomed is now fully focused on its core competency and leading position in the self-injection systems market. Ypsomed is proposing to double the dividend to CHF 4.40 per share (previous year: CHF 2.20).
